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ABSTRACT
Intercellular exchange of protein and RNA-
containing microparticles is an increasingly impor-
tant mode of cell–cell communication. Here we
investigate if mesenchymal stem cells (MSCs)
known for secreting therapeutic paracrine factors
also secrete RNA-containing microparticles. We
observed that human embryonic stem cell (hESC)-
derived MSC conditioned medium contained small
RNAs (less than 300nt) encapsulated in cholesterol-
rich phospholipid vesicles as evidenced by their
RNase sensitivity only in the presence of a
sodium dodecyl sulfate-based cell lysis buffer,
phospholipase A2 and a chelator of cholesterol,
cyclodextrin and the restoration of their lower than
expected density by detergent or phospholipase A2
treatment. MicroRNAs (miRNAs) such as hsa-let-7b
and hsa-let-7g were present in a high precursor
(pre)- to mature miRNA ratio by microarray
analysis and quantitative reverse transcription–
polymerase chain reaction. The pre-miRNAs were
cleaved to mature miRNA by RNase III in vitro.
High performance liquid chromatography-purified
RNA-containing vesicles have a hydrodynamic
radius of 55–65nm and were readily taken up by
H9C2 cardiomyocytes. This study suggests that
MSCs could facilitate miRNA-mediated inter-
cellular communication by secreting microparticles
enriched for pre-miRNA.
INTRODUCTION
The proper functioning of a multicellular organism
requires an intricate intercellular communication system
to ensure proper coordination among diﬀerent cell and
tissue types. Cell–cell communication in most mammalian
systems is highly sophisticated and involves multiple
modes of communication. These include the use of
electrical impulses in the neural tissues, small chemicals
such as amines and steroids, peptides, lipids and gases.
Increasingly, intercellular exchange of microparticles is
seen as an important mode of intercellular communication
(1). Microparticles are lipid vesicles that are <1mmi n
diameter, and are secreted by cells and platelets (2–6).
They have been implicated in health and diseases (7).
Many cell types are known to secrete microparticles and
these include some cancer cells (3), neurons (8) and many
of the vascular and hematopoietic cell types such as
endothelial cells, dendritic cells and B cells (9).
Mesenchymal stem cells (MSCs), derived from adult
bone marrow, have emerged as one of the most promising
stem cell types for treating cardiovascular disease (10), and
MSC is known to exert its therapeutic eﬀects via secreted
trophic factors (11–14). It is therefore possible that MSCs
also secrete microparticles. To test this hypothesis, highly
proliferative MSCs derived from human embryonic stem
cells (hESCs) were used, as these cells are amenable
to large-scale production of secretion in the form of
conditioned medium (CM) (15). As recent reports have
demonstrated that some microparticles contain RNA
(16–19), we speciﬁcally investigated if hESC-derived
MSCs secrete RNA-containing microparticles.
We were able to extract RNA from culture medium
conditioned by hESC–MSCs. The extracted RNAs were
small and were less than 300nt. These RNAs were resis-
tant to RNase unless the CMs were pretreated with a cell
lysis buﬀer, cyclodextrin, a chelator of cholesterol and
phospholipase A2, indicating that these RNAs were
encapsulated in a cholesterol-rich, phospholipid vesicle.
The RNAs in the CM have a much lower than expected
buoyant density of 1.11–1.15g/ml on sucrose density
gradient. Treatment of the CM with a cell lysis buﬀer or
a mixture of cyclodextrin and phospholipase A2 increased
the buoyant density of the RNA to 1.15–1.18g/ml and
1.13–1.16g/ml, respectively. Microarray analysis for the
presence of microRNAs (miRNAs) revealed that the
secreted RNA contained many miRNAs that were essen-
tially a subset of those in MSCs. Quantitative reverse
transcription–polymerase chain reaction (qRT–PCR)
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revealed that they were present predominantly in the
precursor (pre)-miRNA form and could be cleaved by
RNase III to form the mature miRNA. Fractionation by
size exclusion using high performance liquid chromato-
graphy (HPLC) resolved the secretion into several
fractions; one of which contained a homogenously sized
population of microparticles with a hydrodynamic radius
of 55–65nm. Only this fraction contained RNA, and pre-
miRNAs were enriched in this HPLC-puriﬁed microparti-
cles. When these puriﬁed microparticles were labeled with
a lipid membrane-intercalating dye, the microparticles
were taken up by the H9C2 rat cardiomyocytes.
MATERIALS AND METHODS
Preparation of CM
As described previously (15), hESC-derived HuES9.E1
MSCs were used (20) for the production of MSC secretion
in the form of CM. To harvest MSC secretion, 80% of the
conﬂuent HuES9.E1 cultures were washed with phoshate-
buﬀered saline (PBS), transferred to a chemically deﬁned,
serum-free culture medium for an overnight incubation,
washed with PBS and cultured in fresh, chemically
deﬁned, serum-free culture medium for 3 days. The CM
which contained MSC secretion was collected, clariﬁed by
centrifugation, concentrated 50 times using 100-kDa MW
cutoﬀ ultraﬁltration membranes (Satorius) and sterilized
by ﬁltration through a 220-nm ﬁlter.
Isolation and detection of RNA
RNA was isolated from CM by adding three volumes
of Trizol LS (Invitrogen) to one volume of CM and
completing the extraction according to the manufacturer’s
protocol. Total RNA and small RNAs from MSC were
puriﬁed using Trizol (Invitrogen) and mirVana
TM miRNA
Isolation Kit (AppliedBiosystems), respectively. RNA was
quantitated using Quant-iTTM RiboGreen RNA Assay
Kit (Invitrogen) and resolved on 1.5% agarose gel con-
taining 8% glyoxal or 15% Novex Tris–borate–EDTA
(TBE)–urea gels (Invitrogen). The separated RNA in the
gels was visualized by ethidium bromide (EB) staining.
For some experiments, CM was pre-incubated with
equal volume of PBS, cell lysis buﬀer (Biovision), 40mM
cyclodextrin (Sigma-Aldrich) or 4000U/ml phospholipase
A2 (Sigma-Aldrich) at 37 C for 30min followed by
addition of one-tenth volume of a 1-mg/ml RNase A
(Roche). These mixtures were then incubated for
another 5min at 37 C. The RNAs were extracted with
Trizol LS and separated on the TBE–urea gels followed
by EB staining.
Sucrose gradient density equilibrium centrifugation
For sucrose gradient density equilibrium centrifugation,
14 sucrose solutions with concentrations from 22.8% to
60% were prepared and layered sequentially in a SW60
ultracentrifuge tube (Beckman Coulter, Inc.) starting with
the most concentrated solution. CM, or pretreated CM,
or RNA MW markers (RiboRuler
TM Low and high
Range RNA Ladder, Fermentas) were loaded on top
before ultracentrifugation for 16.5h at 200000g,4  C
in a SW60Ti rotor (Beckman Coulter, Inc.). After
centrifugation, the gradients were removed from the top
in 13 fractions, and the density of each fraction was
calculated by weighing a ﬁxed volume of each fraction.
Some of the CM samples were pretreated with an
equal volume of lysis buﬀer (Biovision) or
phospholipase A2 and cyclodextrin at a ﬁnal concentra-
tion of 2000U/ml or 40mM, respectively, before being
loaded on sucrose gradient density equilibrium
centrifugation. The lysis buﬀer was added to CM in a
1:1 volume ratio with a cocktail of protease inhibitor
(Halt Protease Inhibitor Cocktail, EDTA-Free, Thermo
Scientiﬁc). The mixture was incubated for 30min at
room temperature with gentle shaking. RNA was
extracted and assayed.
Protein analysis
Analysis of proteins by western blot hybridization was
performed using standard protocols. Brieﬂy, proteins
were denatured, separated on 4–12% polyacrylamide
gels, electroblotted onto a nitrocellulose membrane and
probed with antibodies against human CD9, Alix (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or DICER
and AGO2 (Abcam, Inc., Cambridge, MA, USA)
followed by horseradish peroxidase-coupled secondary
antibodies against the primary antibody (Santa Cruz
Biotechnology). The blot was then incubated with
a chemiluminescent HRP substrate and exposed to an
X-ray ﬁlm.
Microarray assay and data process
The microarray experiments were performed by LC
Sciences (www.LCsciences.com) with small RNA prepara-
tion from two independently prepared samples of MSC or
CM. The microarray hybridizaton was performed in
duplicate. In the ﬁrst experiment, MSC RNA samples
were labeled with Cy5, and CM RNA samples were
labeled with Cy3. In the second experiment, the dyes
were swopped. The RNAs were labeled with Cy5 or Cy3
and hybridized with the preloaded probes. The data in
each experiment were analyzed using standard data
analysis that includes the determination of detectable
signals, calculation of signal intensities and calculation
of diﬀerential ratios. First, the background was sub-
tracted. Background is determined using a regression-
based background mapping method. The regression was
performed on 5–25% of the lowest intensity data points
excluding blank spots. Raw data matrices were then
subtracted by the background matrix. With background
subtraction, Cy3/Cy5 channel normalization was carried
out using a LOWESS (locally weighted regression)
method on the background-subtracted data. The normal-
ization removed system-related variations, such as sample
amount variations, diﬀerent labeling dyes and signal gain
diﬀerences of scanners so that biological variations can be
faithfully revealed. A transcript was listed as detectable
if it met at least two conditions: signal intensity higher
than 3  (background SD) and spot CV<0.5. CV was
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probes are found on an array, a transcript is listed as
detectable only if the signals from at least 50% of the
repeating probes are above detection level. After the nor-
malization, the P-values of the diﬀerence between Cy3 and
Cy5 signals were calculated and diﬀerences were signiﬁ-
cant if P<0.01.
Analysis of mature or pre-miRNA by qRT–PCR
To detect mature miRNA in MSC or CM, small RNAs
of 10ng were converted into cDNA and resuspended in
15ml using TaqMan microRNA Reverse Transcription
Kit (Applied Biosystems) according to manufacturer’s
protocol. PCR reaction for each RNA sample was
performed in triplicate, with 1ml cDNA and 10mlo f
TaqMan 2X Universal PCR Master Mix (No
AmpErase UNG, Applied Biosystems) in 20ml reaction
volume in a StepOne Plus Realtime PCR system (Applied
Biosystems). The thermal cycling parameters were one
cycle of 95 C of 10min followed by 40cycles of 95 Co f
15s and then one cycle of 60 C of 60s. The primers used
were TaqMan primers, hsa-let-7b (Cat AB Assay
ID_000378, Applied Biosystems) and hsa-let-7g (Cat AB
Assay ID_000383, Applied Biosystems).
For qRT–PCR detection of pre-miRNAs, the primers
were designed using Primer Express  Software Version
3.0 (Applied Biosystems) as previously described (21).
In order to convert to cDNA, 10ng of the RNA sample
was denatured with 10pmol of the lower primer in a 12-ml
reaction volume at 80 C for 5 min. The RNA and lower
primer were then annealed at 60 C for 5min and then
cooled to room temperature. RNase inhibitor, 5 
reaction buﬀer, dNTPs, DTT and the Thermoscript
reverse transcriptase (Invitrogen) were added, as recom-
mended by the manufacturer. The reaction mixture was
incubated for 45min at 60 C followed by 5min incubation
at 85 C. PCR was then performed using one-tenth of the
reaction mixture containing cDNA with a SYBR green
PCR Master Mix (Applied Biosystems) in 20ml reaction
volume. The PCR parameters were one cycle of 15s at
95 C and 40cycles of 1min at 60 C. PCR reactions were
performed in triplicate. Primer sequences for hsa-let-7b
pre-miRNA (accession number MI0000063, http://
microrna.sanger.ac.uk) were 50TGAGGTAGTAGGTTG
TGTGGT30 and 50GGAAGGCAGTAGGTTGTA
TAG30; and for hsa-let-7g pre-miRNA (accession
number MI0000137, http://microrna.sanger.ac.uk) 50GT
AGTAGTTTGTACAGTTTGAGGGT30 and 50GGCA
GTGGCCTGTACAGT30. The primer sets for primary
hsa-let-7b and hsa-let-7g were 50GCCAGGCAGGGGC
TGGTGCTGG30,5 0GGAAGGCAGTAGGTTGTATA
G30 and 50TCCTGTCTCAAGTGCATCCTGAAG30,
50GGCAGTGGCCTGTACAGT30, respectively.
To test whether the pre-miRNAs can be processed
into mature miRNA in vitro, the RNAs were treated
with RNase III. Brieﬂy, 100ng RNAs from MSC or CM
were incubated with 1U RNase III (Applied Biosystems)
in 10ml volume for 30min at 37 C, and then heated at
85 C for 20min. One-tenth volume of the RNase III-
treated reaction mixture or without treated was converted
into cDNA using primers for mature miRNA or pre-
miRNAs as mentioned above.
HPLC fractionation and dynamic light scattering analysis
The instrument setup consisted of a liquid chromatog-
raphy system with a binary pump, an auto injector, a
thermostated column oven and a UV–visible detector
operated by the Class VP software from Shimadzu
Corporation (Kyoto, Japan). The chromatography
columns used were TSK Guard column SWXL,
6 40mm and TSK gel G4000 SWXL, 7.8 300mm
from Tosoh Corporation (Tokyo, Japan). The following
detectors, Dawn 8 (light scattering), Optilab (refractive
index) and QELS (dynamic light scattering) were con-
nected in series following the UV–visible detector.
The last three detectors were from Wyatt Technology
Corporation (CA, USA) and were operated by the
ASTRA software. The components of the sample were
separated by size exclusion, i.e. the larger molecules will
elute before the smaller molecules. The eluent buﬀer used
was 20mM phosphate buﬀer with 150mM of NaCl at pH
7.2. This buﬀer was ﬁltered through a pore size of 0.1mm
and degassed for 15min before use. The chromatography
system was equilibrated at a ﬂow rate of 0.5ml/min until
the signal in Dawn 8 stabilized at  0.3 detector voltage
units. The UV–visible detector was set at 220nm and the
column was oven equilibrated to 25 C. The elution
mode was isocratic and the run time was 40min.
The volume of sample injected ranged from 50mlt o
100ml. The percent area of the exosome peak versus all
other peaks was integrated from the UV–visible detector.
The hydrodynamic radius, Rh, was computed by the
QELS and Dawn 8 detectors. The highest count rate
(in Hertzs) at the peak apex was taken as the Rh.
Peaks of the separated components visualized at 220nm
were collected as fractions for further characterization
studies.
Uptake of labeled microparticles by H9C2 cardiomyocytes
The H9C2 cells were cultured in high-glucose Dulbecco’s
modiﬁed Eagle medium (DMEM) medium containing
10% fetal calf serum, 1% glutamine–penicillin–streptomy-
cin and 1% sodium pyruvate (all from Invitrogen). For
microparticle labeling, 50mlo f3 mg HPLC-puriﬁed
microparticles or PBS was mixed with 0.2ml of ﬂuorescent
labeling dye PKH67 (Sigma-Aldrich) at room temperature
for 5min. The labeled mixtures were dialyzed in PBS for
24h using D-Tube Dialyzer (6–8kDa) (Novagen). After
that, one volume of the labeled mixtures and four volumes
of culture medium were added into H9C2 cells in 48-well
plate. After another 2-h incubation, the cells were ﬁxed in
4% paraformaldehyde (Sigma-Aldrich) for 10min and
stained with DAPI (300nM) (Roche) for 5min. The cell
images were taken at 400  magniﬁcation using Olympus
IX-71 microscope and DP-70 camera. The images were
merged with DP manager software. The scale bar is
200mm.
Statistical analysis
Statistical signiﬁcance was analyzed using Student’s t-test.
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Presence of RNA in the secretion of MSCs
To determine if MSCs secrete RNA, MSC CM was
extracted for RNA using standard RNA extraction meth-
odology. A typical CM was prepared by collecting a chem-
ically deﬁned medium that had been conditioned by MSC
for 3 days and then concentrating the medium 50 times
with a 100-kDa ﬁlter. The average RNA yield was 5–6mg
RNA/mg protein. When resolved on either a denaturing
glyoxal agarose gel or 15% TBE–urea gel, it was observed
that the RNA contained mainly small RNAs of less than
300nt with undetectable levels of 18S and 28S ribosomal
RNAs (Figure 1).
Secreted RNAs were small and susceptible to RNase
A only in the presence of a sodium dodecyl sulfate-based cell
lysis buﬀer, cyclodextrin or phospholipase A2
Recent reports of RNA secretion have demonstrated
that these RNAs are secreted in phospholipid vesicles
known as exosomes (16–19). Therefore, to determine if
the secreted RNAs in the CM were also in phospholipid
vesicles, CM was pretreated with RNase A, or RNase A in
the presence of a SDS-based cell lysis buﬀer, cyclodextrin
or phospholipase A2 before RNA extraction. RNase A
treatment alone did not reduce RNA yield or aﬀect
the size distribution of RNA in the CM (Figure 2A).
However, RNase A treatment in the presence of a SDS-
based cell lysis buﬀer, cyclodextrin or phospholipase A2
either completely or partially degraded the RNA in the
CM. The size distribution of the secreted RNAs was
also not altered when the extraction was performed
in the presence of RNAse inhibitors, or in the presence
of a SDS-based cell lysis buﬀer, cyclodextrin or
phospholipase A2 without RNase (Figure 2B). Together,
these observations suggested that the RNA was protected
from RNase activity by a cholesterol-rich phospholipid
membrane unless the membrane was ﬁrst dissolved by a
SDS-based cell lysis buﬀer, cyclodextrin that chelates and
extracts cholesterol or degradation by an phospholipid
degrading enzyme, phospholipase A2.
Secreted RNAs have a buoyant density of 1.11–1.15g/ml
If secreted RNAs were encapsulated in lipid vesicles, they
should be precipitated by ultracentrifugation and would
be expected to have a ﬂotation density of lipid vesicles in
the range of 1.10–1.18g/ml (22,23). By centrifuging the
CM ﬁrst at 10000g for 30min and then ultracentrifuging
the supernatant at 200000g for 2h followed by RNA
extraction from the supernatant and pellet of each
centrifugation, we detected RNA in the supernatant
after the 10000g centrifugation and enriched in the
pellet after 200000g ultracentrifugation (Figure 3A).
Fractionation of the CM into 13 fractions by sucrose
density gradient equilibrium ultracentrifugation revealed
that unlike puriﬁed RNA molecular weight (MW)
markers with a buoyant density of 1.15–1.18g/ml, the
secreted RNAs have a lower buoyant density of
1.11–1.15g/ml (Figure 3B). This buoyant density was
increased after the CM was treated with a combination
of phospholipase A2 and cyclodextrin (1.13–1.16g/ml)
or an SDS-based lysis buﬀer (1.15–1.18g/ml) (Figure 3B
and C). Together, these observations conﬁrmed that the
secreted RNAs were encapsulated in cholesterol-rich
phospholipid vesicles.
Secreted RNA contained miRNAs
As the secreted RNAs were of less than 300nt, we tested
the RNAs for the presence of miRNAs by performing
microarray hybridization. MSC expressed at least 151
miRNAs including some passenger miRNA sequences
denoted as miRNA* (Table 1). Sixty miRNAs were
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Figure 2. Secreted RNAs were sequestered in phospholipid vesicles.
(A) Untreated CM or CM pretreated with SDS-based lysis buﬀer,
cyclodextrin or phospholipase A2 was incubated with RNase A.
After incubation, the CMs were extracted for RNA and the RNAs
were resolved on a 15% TBE–urea gel. (B) RNA was extracted from
CM without RNase inhibitor (lane 2), with RNase inhibitor (lane 3)
or CM pretreated with cyclodextrin (lane 4), SDS-based lysis buﬀer
(lane 5) or phospholipase A2 (lane 6).
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Figure 1. Resolving secreted RNAs by size on agarose and poly-
acrylamide gels. (A) Cellular or secreted RNAs were separated on
a 1.5% glyoxal agarose gel. (B) Cellular or secreted RNAs were
separated on a 15% TBE–urea gel. The MW markers used were
denatured 10-bp DNA ladder, high-range RNA ladder (0.2–6kb) or
low-range RNA ladder (0.1–1kb).
218 Nucleic Acids Research, 2010,Vol. 38,No. 1detected in the CM. Of these, 45 were also found in MSCs.
The remaining 15 were not detected in MSCs and they
were probably masked by the relative high abundance of
the other miRNA species in the MSCs (see ‘The relative
abundance of miRNAs in the CM and MSCs’ in
Supplementary Material). A most notable observation
was that 9 of the 13 members in one of the most highly
conserved and developmentally important human let-7
family (24,25) were expressed in MSCs. They were hsa-
let-7a, hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7e,
hsa-let-7f, hsa-let-7g, hsa-let-7i and hsa-miR-98, but not
hsa-let-7j, hsa-let-7k and hsa-miR-202. Of these, only hsa-
let-7a, hsa-let-7b, hsa-let-7c and hsa-let-7d were detected
in the CM. The passenger miRNA sequences of hsa-let-7b
and hsa-let-7d were also detected in the CM and not
detectable in MSCs. These diﬀerences suggested that
secretion of miRNAs including passenger miRNA
sequences is a selective, and not a random process by
MSCs. The microarray analysis also revealed the
presence of miRNA-923, and miRNA-923 has recently
been conﬁrmed as a degradative product of ribosomal
RNA (http://microrna.sanger.ac.uk/cgi-bin/sequences/
mirna_entry.pl?acc=MI0005715). This suggested that
while the secretion did not contain intact ribosomal
RNA, it contained degraded ribosomal RNA and
possibly degraded mRNA.
Secreted RNA contained pre-miRNA
The detection of passenger miRNA sequences by
microarray analysis suggested that either pre-miRNAs
or passenger miRNAs, which are normally degraded,
were present in both CM and their cell source. The
microarray analysis also suggested that passenger
miRNA sequences for some of the miRNAs were
present at a relatively higher level in the CM than in
their cell source. To evaluate these observations, we deter-
mined the ratio of pre-miRNA and its mature miRNA
levels for two members of the let-7 family, namely hsa-
let-7b and hsa-let-7g by qRT–PCR. The ratios of pre- to
mature miRNA level for hsa-let-7b and hsa-let-7g were
determined before and after treatment with RNase III to
cleave any pre-miRNAs from approximately a 70nt
RNA species to approximately a 22nt mature miRNA.
We observed that RNase III treatment caused a preferen-
tial loss of RNA in the 50- to 100-nt region (Figure 4A).
Before RNase III treatment, the ratio of pre-miRNA to
mature miRNA for hsa-let-7b and hsa-let-7g in the secre-
tion after normalizing to that in MSC were 169.1±12.1
(P<0.0001) and 1077.8±123.51 (P<0.0001), respec-
tively (Figure 4B). After RNase III treatment, the ratio
of pre- to mature miRNA was reduced for hsa-let-7b
and hsa-let-7g in both CM and MSC (Figure 4B). The
decrease in these ratios was due to a decrease in pre-
miRNA level coupled with a concomitant increase in
mature miRNA level as reﬂected by the respective
increases and decreases in Ct values (Figure 4C). To deter-
mine if pri-miRNA was present in the secretion, RT–PCR
was performed using primers speciﬁc for hsa-let-7b and
hsa-let-7g pri-miRNAs (Figure 4D). Hsa-let-7b and hsa-
let-7g pri-miRNAs were not detected in the secretion. As
mature miRNAs are biologically functional only when
they are associated with RNA-induced silencing complex
(RISC), we examined the possibility of association of the
secreted mature miRNAs with RISC by assaying for the
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Figure 3. Precipitation of RNA-containing vesicles or ﬂotation density
of RNA in a sucrose gradient density. (A) The CM was centrifuged at
10000g for 30min. An aliquot of the supernatant was then
ultracentrifuged at 200000g for 2h at 4 C in a SW60Ti rotor (Beckman
Coulter, Inc.). RNA was extracted from the supernatant (S) and the pellet
(P) after each centrifugation, and the RNAs were resuspended in TE. The
volume of each RNA sample was adjusted to the volume used for the
centrifugation and equal volume of each fraction was then resolved on a
15% TBE–urea gel. (B) CM treated with PBS, phospholipase A2 and
cyclodextrin or SDS-based lysis buﬀer were loaded on a preformed
sucrose density gradient as described in ‘Materials and Methods’
section and ultracentrifuged for 16.5h at 200000g at 4 C. The gradients
were removed from the top in 13 fractions and the density of each fraction
was calculated by weighing a ﬁxed volume of each fraction. The fractions
were extracted for RNA, and the RNA yield for each fraction was
assayed. The RNA concentration was then normalized to the highest
concentration in each gradient. RNA from each fraction in a gradient
was resolved on a 15%TBE–urea gel. CMtreated with PBS is indicated in
upper panel, CM treated with phospholipase A2 and cyclodextrin in
middle panel and CM treated with SDS-based lysis buﬀer in lower
panel. (C) The relative RNA yield for each fraction was plotted against
the density of the fraction.
Nucleic AcidsResearch, 2010, Vol.38,No. 1 219presence of Dicer and Ago2, the main components of
RISC by western blot hybridization (Figure 4E). Both
the proteins were present in MSC but not detected in
the secretion. Together, these observations suggested
that both hsa-let-7b and hsa-let-7g miRNAs were
present as mature and pre-miRNAs in both CM and
MSCs but were secreted predominantly as pre-miRNA,
and these pre-miRNAs can be cleaved by RNase III to
form mature miRNAs. The secreted mature miRNAs were
not associated with RISC as the major RISC protein
components were not present in the secretion.
Puriﬁcation of homogenously sized microparticles by size
exclusion on HPLC
As the miRNAs were encapsulated in lipid vesicles, we
hypothesized that these vesicles could be isolated by size
exclusion on a HPLC. Fractionation of the CM and NCM
Table 1. Detection of 166 miRNA in MSC and CM as determined by microarray
hsa-let-7a hsa-miR-151-3p hsa-miR-23a hsa-miR-424
hsa-let-7b hsa-miR-151-5p hsa-miR-23a* hsa-miR-424*
hsa-let-7b* hsa-miR-152 hsa-miR-23b hsa-miR-425
hsa-let-7c hsa-miR-155 hsa-miR-24 hsa-miR-425*
hsa-let-7d hsa-miR-15a hsa-miR-24-2* hsa-miR-454
hsa-let-7d* hsa-miR-15b hsa-miR-25 hsa-miR-455-3p
hsa-let-7e hsa-miR-16 hsa-miR-26a hsa-miR-483-5p
hsa-let-7f hsa-miR-17 hsa-miR-26b hsa-miR-484
hsa-let-7g hsa-miR-181a hsa-miR-27a hsa-miR-491-5p
hsa-let-7i hsa-miR-181a* hsa-miR-27b hsa-miR-503
hsa-miR-100 hsa-miR-181a-2* hsa-miR-27b* hsa-miR-505*
hsa-miR-103 hsa-miR-181b hsa-miR-28-3p hsa-miR-532-5p
hsa-miR-106a hsa-miR-181c hsa-miR-28-5p hsa-miR-572
hsa-miR-106b hsa-miR-181d hsa-miR-296-5p hsa-miR-574-3p
hsa-miR-107 hsa-miR-185 hsa-miR-29a hsa-miR-574-5p
hsa-miR-10a hsa-miR-186 hsa-miR-29c hsa-miR-575
hsa-miR-122 hsa-miR-187* hsa-miR-30a hsa-miR-584
hsa-miR-1224-5p hsa-miR-18a hsa-miR-30a* hsa-miR-612
hsa-miR-1228 hsa-miR-18b hsa-miR-30b hsa-miR-625
hsa-miR-1234 hsa-miR-191 hsa-miR-30c hsa-miR-629
hsa-miR-1237 hsa-miR-191* hsa-miR-30d hsa-miR-638
hsa-miR-1238 hsa-miR-192 hsa-miR-30e hsa-miR-663
hsa-miR-124 hsa-miR-193a-5p hsa-miR-30e* hsa-miR-671-5p
hsa-miR-125a-3p hsa-miR-195 hsa-miR-31 hsa-miR-708
hsa-miR-125a-5p hsa-miR-197 hsa-miR-31* hsa-miR-744
hsa-miR-125b hsa-miR-198 hsa-miR-320 hsa-miR-765
hsa-miR-126 hsa-miR-199a-3p hsa-miR-324-5p hsa-miR-766
hsa-miR-128 hsa-miR-199a-5p hsa-miR-328 hsa-miR-768-3p
hsa-miR-130a hsa-miR-199b-5p hsa-miR-330-3p hsa-miR-768-5p
hsa-miR-130b hsa-miR-19b hsa-miR-331-3p hsa-miR-769-5p
hsa-miR-132 hsa-miR-20a hsa-miR-335 hsa-miR-877
hsa-miR-137 hsa-miR-20b hsa-miR-342-3p hsa-miR-923
hsa-miR-140-3p hsa-miR-21 hsa-miR-345 hsa-miR-92a
hsa-miR-143 hsa-miR-210 hsa-miR-34a hsa-miR-92b
hsa-miR-145 hsa-miR-212 hsa-miR-34a* hsa-miR-93
hsa-miR-145* hsa-miR-214 hsa-miR-361-5p hsa-miR-933
hsa-miR-146a hsa-miR-22 hsa-miR-362-3p hsa-miR-940
hsa-miR-146b-5p hsa-miR-22* hsa-miR-362-5p hsa-miR-98
hsa-miR-148b hsa-miR-221 hsa-miR-365 hsa-miR-99a
hsa-miR-149 hsa-miR-221* hsa-miR-374b hsa-miR-99b
hsa-miR-149* hsa-miR-222 hsa-miR-421
hsa-miR-150* hsa-miR-222* hsa-miR-423-5p
White font and black shade 15 miRNAs detected only in CM
Black font and gray shade 12 miRNAs detected with 2 fold higher in CM versus MSC
Black font and underline 33 miRNAs detected in MSC and CM
Black font 106 miRNAs detected only in MSC
Two independent samples from MSC or CM were analyzed in duplicate. A transcript was listed as
detectable if it met at least two conditions: signal intensity higher than 3 (background SD) and spot
CV<0.5. CV was calculated by (SD)/(signal intensity). When repeating probes are present on an array,
a transcript is listed as detectable only if the signals from at least 50% of the repeating probes are above
detection level. Small RNA was prepared from MSC and CM, and hybridized to a microarray chip
containing 723 probes, which detects miRNA transcripts listed in Sanger miRBase Release 10.1.
220 Nucleic Acids Research, 2010,Vol. 38,No. 1revealed the presence of four fractions unique to the CM,
suggesting that these were secreted by the MSCs (Figure
5A). Fractions 2–4 contained proteins with decreasing
MW with the highest MW in Fraction 2 and the lowest
in Fraction 4, while Fraction 1 contained proteins with
MW range that encompassed those in Fractions 2–4.
RNA was present only in the fastest eluting Fraction 1
(Figure 5B). Two proteins commonly associated with
exosomes, CD9 (20Kd) and Alix (100Kd), were found
almost exclusively in this fraction in spite of their large
size diﬀerence (Figure 5B). Together, these suggested that
the RNA was present in phospholipid vesicles known as
exosomes (19). Unlike RNA extracted from CM, the RNA
in the HPLC-puriﬁed microparticles had a narrower MW
range between 50 and 100nt instead between 10 and 300nt
range of RNA extracted from CM, suggesting that
pre-miRNAs might be further enriched in this fraction.
The ratio of pre- to mature miRNA for hsa-let-7b and
hsa-let-7g as determined by qRT–PCR was signiﬁcantly
increased by a factor of 44.55±5.05 (P=0.0001) and
11.19±2.01 (P=0.0009), respectively (Figure 5C). The
RNAs in the HPLC-puriﬁed fraction had a buoyant
density of 1.11–1.15g/ml (Figure 5D). The size of the
particles in the ﬁrst fraction was suﬃciently homogenous
such that their hydrodynamic radius was 55–65nm as
determined by dynamic light scattering. The particle sizes
in the other fraction were too heterogeneous to be
determined.
Uptake of phospholipid microparticles by H9C2
cardiomyocytes
Since miRNAs exert their biological eﬀects intracellularly,
we investigate if the HPLC-puriﬁed RNA-containing
microparticles could be taken up by H9C2 cardio-
myocytes. The puriﬁed microparticles were labeled with
a ﬂuorescent phospholipid membrane-intercalating dye
PKH67 and fed to H9C2 cardiomyocytes. Within 2h,
the ﬂuorescent label was observed in the cytoplasm but
not nucleus of the cells, suggesting that the HPLC-
puriﬁed microparticles can be taken up intracellularly
into the cytoplasm (Figure 6).
DISCUSSION
The therapeutic eﬀects of MSC transplantation on cardio-
vascular tissue repair have been attributed in part to its
paracrine secretion (11–14). In support of this hypothesis,
we have previously demonstrated that secretion from
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Figure 4. Cleavage of pre-miRNA to mature miRNA by RNase III. (A) Extracted RNA was treated with RNase III and separated with untreated
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Nucleic AcidsResearch, 2010, Vol.38,No. 1 221hESC-derived MSCs was cardioprotective in both pig and
animal models of myocardial ischemia and reperfusion
injury (26). Since microparticles are increasingly found
in the secretion of many cell types with potentially impor-
tant functions in health and diseases, we investigated
if MSC secretion also contains microparticles. As
microparticles have also been shown to contain RNAs,
we speciﬁcally investigate if MSCs secrete RNA-
containing microparticles. Here we characterized a
chemically deﬁned culture medium conditioned by
hESC-derived MSCs (15) and observed that this CM
contained RNA encapsulated in cholesterol-rich phos-
pholipid vesicles as evidenced by their susceptibility to
RNase digestion only in the presence of a SDS-based
lysis buﬀer, a cholesterol chelator, cyclodextrin and
phospholipase A2. Consistent with this, these RNAs
also have a buoyant density of a lipid vesicle, i.e. 1.11–
1.15g/ml, and this density was sensitive to SDS,
phospholipase A2 and cyclodextrin. Unlike cellular
RNAs, these secreted RNAs were mainly small RNAs
with no detectable 18S or 28S RNAs or RNAs greater
than 500nt, suggesting that secretion of these RNAs was
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with antibodies against CD9 and Alix. (C) RNA extracted from F1 fraction and unfractionated CM was assayed for pre- and mature forms of hsa-
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222 Nucleic Acids Research, 2010,Vol. 38,No. 1not a random cellular process but a selective process that
targets small RNAs such as miRNAs and, most possibly,
other small non-coding RNAs (27) or RNA degradative
intermediates, but not the more abundant intact mRNAs
or ribosomal RNAs present in cells.
The recent reports of RNA secretion in microparticles
have led to the postulation that these vesicles of RNAs
could serve as vehicles of genetic communication between
cells (19,28). It has been shown that mRNAs in these
secreted RNAs could be translated into proteins after
taken up by the cells. However, the physiological rele-
vance of such mRNAs to cellular functions remains to
be determined as mRNAs constitute a very small propor-
tion of the secreted RNAs. Instead, most of the secreted
RNAs are small RNAs, and mature miRNAs of 17–22nt
were implicated in the composition of these small RNAs
(19,28). However, it is unlikely that these secreted mature
miRNAs play any biological functions as these miRNAs
were not associated with RISC, and being mature
miRNA, they can no longer be loaded into RISC to
eﬀect their functions. Incorporation of mature miRNA
into RISC is mediated through the loading of pre-
miRNA into RISC followed by cleavage of pre-miRNA
by Dicer (29–31), whereupon the guide or mature
miRNAs are then incorporated into the RISC while the
passenger miRNAs are discarded (32–34).
Our observations that MSCs preferentially secrete
miRNA in the precursor instead of the mature form and
that these pre-miRNAs were enriched in microparticles,
possibly exosomes, that were readily taken up by cells
suggest that there are important physiological functions
underlying this secretion. They suggest that MSC can
potentially exert miRNA-mediated biological eﬀects
on other cells through the secretion of pre-miRNA
in microparticles. However, the biological function of
secreted pre-miRNAs is presently diﬃcult to assess at
this time as we still cannot accurately predict or determine
the targets of miRNAs. As such, the physiological
relevance of hsa-let-7b and hsa-let-7g pre-miRNA
remains to be determined.
In conclusion, our study demonstrated that the
paracrine secretion of MSCs contains RNAs besides
proteins and lipids. Most of this secreted RNAs were
encapsulated in phospholipid vesicles, and these vesicles
can be puriﬁed as a population of homogenously sized
particles by size exclusion on a HPLC. These particles
contained small RNAs that included miRNAs and also
some degraded ribosomal RNA intermediates. The
miRNAs consisted mainly of biologically functional pre-
miRNAs. As the microparticles can be readily taken up by
cells, our ﬁndings implicate a novel intercellular role for
miRNA.
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Figure 6. HPLC-puriﬁed cardioprotective microparticles can be taken by H9C2 cardiomyocytes. The HPLC-puriﬁed cardioprotective microparticles
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